Premium
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry
Author(s) -
Redder Louise,
Klausen Tobias W.,
Vangsted Annette Juul,
Gregersen Henrik,
Andersen Niels F.,
Pedersen Robert S.,
Szabo Agoston G.,
Frederiksen Mikael,
Frølund Ulf C.,
Helleberg Carsten,
Nielsen Lene Kongsgaard,
Pedersen Per T.,
Salomo Morten,
Gimsing Peter,
Frederiksen Henrik,
Abildgaard Niels
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16806
Subject(s) - medicine , multiple myeloma , hazard ratio , transplantation , cohort , autologous stem cell transplantation , population , proportional hazards model , oncology , surgery , confidence interval , environmental health
Summary In 2019 the UK Myeloma Research Alliance introduced the Myeloma Risk Profile (MRP) for prediction of outcome in patients with newly diagnosed multiple myeloma (MM), ineligible for autologous stem cell transplantation. To validate the MRP in a population‐based setting we performed a study of the entire cohort of transplant ineligible MM patients above 65 years in the Danish National MM Registry. Our data confirmed the value of the MRP. In a cohort of 1,377 patients, the MRP score separated patients into three distinct risk‐groups with an observed hazard ratio of 2.91 for early death in high‐risk versus low‐risk patients.